Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRO POWR Grades
- SPRO scores best on the Quality dimension, with a Quality rank ahead of 64.81% of US stocks.
- SPRO's strongest trending metric is Growth; it's been moving down over the last 161 days.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 4.06% of US stocks).
SPRO Stock Summary
- The ratio of debt to operating expenses for Spero Therapeutics Inc is higher than it is for about just 12.55% of US stocks.
- SPRO's price/sales ratio is 23.2; that's higher than the P/S ratio of 92.89% of US stocks.
- Revenue growth over the past 12 months for Spero Therapeutics Inc comes in at 57.59%, a number that bests 87.57% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Spero Therapeutics Inc are GSIT, APM, FBIO, LOGC, and AGLE.
- SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Valuation Summary
- In comparison to the median Healthcare stock, SPRO's EV/EBIT ratio is 124.91% lower, now standing at -7.3.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
Below are key valuation metrics over time for SPRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SPRO | 2021-08-31 | 33.7 | 6.9 | -8.2 | -7.3 |
| SPRO | 2021-08-30 | 31.6 | 6.4 | -7.7 | -6.8 |
| SPRO | 2021-08-27 | 29.7 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-26 | 29.1 | 5.9 | -7.1 | -6.2 |
| SPRO | 2021-08-25 | 29.6 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-24 | 28.4 | 5.8 | -6.9 | -6.1 |
SPRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRO has a Quality Grade of C, ranking ahead of 28.84% of graded US stocks.
- SPRO's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 1 | -1.651 |
| 2021-03-31 | 0.108 | 1 | -1.872 |
| 2020-12-31 | 0.072 | 1 | -2.390 |
| 2020-09-30 | 0.094 | 1 | -2.720 |
| 2020-06-30 | 0.110 | 1 | -2.104 |
| 2020-03-31 | 0.108 | 1 | -1.684 |
SPRO Price Target
For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $38.17 | Average Broker Recommendation | 1.58 (Moderate Buy) |
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
| Current price | $12.05 | 52-week high | $22.24 |
| Prev. close | $12.26 | 52-week low | $11.69 |
| Day low | $11.96 | Volume | 134,870 |
| Day high | $12.99 | Avg. volume | 146,075 |
| 50-day MA | $14.38 | Dividend yield | N/A |
| 200-day MA | $15.19 | Market Cap | 389.50M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection ProgramThe FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed. The FDA's decision to lift the hold follows Spero's submission of a comprehensive study report with detailed analyses from the NHP toxic |
Spero (SPRO) Application for UTI Drug Gets Priority ReviewSpero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review. |
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. “We are very pleased with the FDA’s decision and eager to bring SPR720 back into the clinic,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero. “Extensive ana |
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including PyelonephritisThe FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections (c |
Spero Therapeutics Urinary-Tract Drug Gets FDA Priority ReviewSpero Therapeutics said the FDA will give priority review to its new-drug application for a drug that treats complicated urinary tract infections in adults. |
SPRO Price Returns
| 1-mo | -12.81% |
| 3-mo | -28.53% |
| 6-mo | -15.91% |
| 1-year | -29.98% |
| 3-year | 49.69% |
| 5-year | N/A |
| YTD | -24.73% |
| 2021 | -17.43% |
| 2020 | 101.66% |
| 2019 | 56.34% |
| 2018 | -47.66% |
| 2017 | N/A |
Continue Researching SPRO
Want to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...